SpineThera, Inc. to collaborate with Mayo Clinic to advance solutions in substance abuse disorder treatment

[Plymouth, MN] June 17, 2024 – SpineThera, Inc., apharmaceutical company specializing in long-acting injectable technology, hasannounced it has entered into a know-how agreement with Mayo Clinic. Thiscollaboration aims to develop long-acting injectable drugs to improve treatmentoutcomes for individuals with substance abuse disorders.

The opioid epidemic remains asignificant public health crisis, impacting millions worldwide. There is a need to develop treatmentoptions that improve outcomes, increase patient access to supervised treatment,and reduce risk associated with existing treatments.

The project will be led by SpineThera CEO, Jeff Missling,and Chair for Addiction Medicine at Mayo Clinic, Tyler Oesterle, M.D.  

Misslingcommented on the significance of the collaboration, “SpineThera’s novel,long-acting injectable technology has potential in multiple therapeutic areas.We are honored to move strategically into substance abuse disorder treatmentthrough this collaboration. Despite multiple approved medications for thetreatment of opioid use disorder, we are still losing too many people to thiscrisis every day and seek to make a difference through our contributions."

By leveraging SpineThera’s long-acting injectabletechnology and Mayo Clinic’s expertise in addiction medicine, thiscollaboration seeks to develop more effective and accessible treatment options.SpineThera is committed to addressing this healthcare challenge and improvingthe lives of individuals affected by substance abuse disorders. 

Mayo Clinic has a financialinterest in the technology referenced in this press release. Mayo Clinic willuse any revenue it receives to support its not-for-profit mission in patientcare, education and research.

AboutSpineThera, Inc.:

SpineThera is aclinical stage pharmaceutical company working to improve the lives of patientsby creating long-acting injectable drugs utilizing its patentedmicro-suspension platform technology. SpineThera’s micro-suspension providesmonths long sustained release of the active pharmaceutical ingredient withsuperior injectability at ultra-high concentrations. Our goal is to developproprietary drugs that offer patients and physicians new treatment options thatreduce risk, improve outcomes, and manage overall treatment costs in marketswith few or no approved drugs.

SpineThera'sflagship investigational drug product, SX600, is a dexamethasone acetatemicro-suspension injection which has been engineered as a targeted,extended-release corticosteroid with the potential to demonstrate asubstantially improved benefit-risk profile compared to current epiduralsteroid injections for radicular leg pain. SpineThera, Inc., is based inMedical Alley, Minnesota, the global epicenter of health innovation and care.For more information visit: www.spinethera.com.
‍

For media inquiries or further information, please contact:

Jeff Missling,CEO

jmissling@spinethera.com

612-508-4795

‍